.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Chubb
Fish and Richardson
QuintilesIMS
Federal Trade Commission
Baxter
Accenture
UBS
Johnson and Johnson

Generated: January 20, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0525237.4

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxo Grp EnglandINCRUSE ELLIPTA umeclidinium bromidePOWDER;INHALATION205382-001Apr 30, 2014RXYesYes➤ Subscribe➤ SubscribeY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Subscribe➤ SubscribeY
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes➤ Subscribe➤ SubscribeY
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes➤ Subscribe➤ SubscribeY
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes➤ Subscribe➤ SubscribeY
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes➤ Subscribe➤ SubscribeY
GlaxosmithklineTRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION209482-001Sep 18, 2017RXYesYes➤ Subscribe➤ SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist